VHL and cancer: For example, VHL-based PROTAC for BCL-xl is more tolerable than BCL-xl inhibitor ATB263, in part due to the relatively low expression of VHL in platelets than in cancer cells, thus reducing potential on-target toxicity (Khan et al., 2019).